| Identification | Back Directory | [Name]
Cimifugin | [CAS]
37921-38-3 | [Synonyms]
CiMitin
Cimifugin
CIMIFUGIN(P)
Cimifugin, 99.5%
Cimifugin USP/EP/BP
Cimifugin (Cimitin)
Cimifugin, 98%, from Saposhnikovia divaricata (Turcz.) Schischk.
(2S)-7-(Hydroxymethyl)-2-(2-hydroxypropan-2-yl)-4-methoxy-2,3-dihydrofuro[3,2-g]chromen-5-one
(S)-2,3-Dihydro-7-(hydroxymethyl)-2-(1-hydroxy-1-methylethyl)-4-methoxy-5H-furo[3,2-g][1]benzopyran-5-one
5H-Furo[3,2-g][1]benzopyran-5-one, 2,3-dihydro-7-(hydroxymethyl)-2-(1-hydroxy-1-methylethyl)-4-methoxy-, (2S)- | [Molecular Formula]
C16H18O6 | [MDL Number]
MFCD23105630 | [MOL File]
37921-38-3.mol | [Molecular Weight]
306.32 |
| Chemical Properties | Back Directory | [Melting point ]
107～109℃ | [Boiling point ]
546.4±50.0 °C(Predicted) | [density ]
1.361±0.06 g/cm3(Predicted) | [storage temp. ]
-20°C | [form ]
powder | [pka]
14.25±0.29(Predicted) | [color ]
White-beige | [Major Application]
pharmaceutical | [InChI]
1S/C16H18O6/c1-16(2,19)13-5-9-11(22-13)6-12-14(15(9)20-3)10(18)4-8(7-17)21-12/h4,6,13,17,19H,5,7H2,1-3H3/t13-/m0/s1 | [InChIKey]
ATDBDSBKYKMRGZ-ZDUSSCGKSA-N | [SMILES]
[o]1c2c([c](cc1CO)=O)c(c3c(c2)O[C@@H](C3)C(O)(C)C)OC |
| Questions And Answer | Back Directory | [Components]
The main components of Cimicifuga are triterpenoid polyoxygenates, chromogen ketones, phenolic acids, various chromones, odontoamol and odontoamicin. Among them, the identified structures are: isoferulic acid, 3-acetyl caffeic acid, caffeic ester glucoside, cimifugin, cimifugin glucoside, 6-isoxanthine nucleoside, cimidahurine, cimidahurinie, D-glucose, sucrose, etc. |
| Hazard Information | Back Directory | [Chemical Properties]
Soluble in methanol, DMSO and other solvents, insoluble in petroleum ether. Derived from the rhizome of Cimicifuga foetida L. | [Uses]
Cimifugin USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Siler Root
- Siler Root Dry Extract
- Siler Root Powder
| [Definition]
ChEBI: Cimifugin is an oxacycle and an organic heterotricyclic compound. | [in vivo]
Cimifugin (Cimitin; 12.5 or 50 mg/kg/day; intragastrically; 2 days) significantly inhibits TSLP and IL-33 in the initial stage of Mice are sensitized and challenged with FITC to establish type 2 atopic dermatitis (AD) model. Simultaneously, Cimifugin reduces the separated gap among the epithelial cells and increased the expression of TJs[1].
| [target]
IFN-γ | IL Receptor | AChE | BChE |
|
|